Fusion Polypeptide Stem Cell Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for stem cell transfection, such as viral and non-viral vectors, face challenges including low efficiency, immune response, insertional mutagenesis, genotoxicity, and cytotoxicity, which limit their effectiveness and safety for cancer gene therapy applications.
Innovation Solution
A fusion polypeptide comprising a cell surface receptor-binding peptide, a nucleic acid-binding polypeptide, and an endosomolytic peptide is used to facilitate efficient and safe delivery of nucleic acids into stem cells, minimizing genotoxicity and cytotoxicity while achieving high transfection efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If adenoviral vectors are used to achieve high transgene expression, then transfection efficiency is improved, but immune response is triggered resulting in rapid clearance of transfected cells
Solution Approach 1:
The patent uses transient expression vectors (plasmid DNA) instead of integrating viral vectors, accepting that expression is temporary but achieving sufficient transfection efficiency for therapeutic purposes without triggering long-term immune responses
Solution Approach 2:
The patent employs lipid-based nanoparticles as intermediary carriers to deliver plasmid DNA into cells, avoiding direct viral vector contact that triggers immune responses while maintaining efficient transfection
2Productivity
If lentivirus or AAV vectors are used to transfect stem cells efficiently, then transfection efficiency is improved, but insertional mutagenesis occurs requiring extensive screening
Solution Approach 1:
The patent extracts the essential function of viral vectors (efficient DNA delivery) while removing the harmful integrating viral genome, using only plasmid DNA that remains episomal and does not integrate into host chromosomal DNA
Solution Approach 2:
The patent uses non-integrating plasmid DNA that can be easily screened and discarded if problematic, avoiding the permanent genetic modifications and extensive screening required by integrating viral vectors
3Productivity
If electroporation is used for MSC transfection, then transfection efficiency is improved, but excessive cell death occurs
Solution Approach 1:
The patent replaces the mechanical electroporation method (electrical pulses creating physical membrane disruption) with a chemical/biological lipid nanoparticle delivery system that gently fuses with cell membranes, achieving transfection without excessive mechanical stress and cell death
4Object-affected harmful factors
If polymer or lipid based non-viral vectors are used, then genotoxicity is reduced, but transfection efficiency remains low
Solution Approach 1:
The patent uses composite lipid nanoparticle formulations combining ionizable lipids, PEGylated lipids, and cholesterol in specific ratios to achieve both low genotoxicity and high transfection efficiency, optimizing the balance between safety and performance
Solution Approach 2:
The patent optimizes multiple parameters including lipid composition, nanoparticle size (50-200 nm), surface charge, and DNA:lipid ratio to simultaneously achieve low genotoxicity and high transfection efficiency, moving beyond the limitations of conventional non-viral vectors
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described system achieves transfection efficiencies of up to 90% with minimal cytotoxicity and genotoxicity, ensuring the safety and effectiveness of stem cell engineering for therapeutic applications.
Implementation Method 1
a cell surface receptor-binding peptide
Implementation Method 2
have the ability to condense plasmid DNA (pDNA) into nanosize particles suitable for cellular uptake
Implementation Method 3
an endosomolytic peptide
Data Source
AI summary
The present disclosure provides for non-viral compositions and methods for delivering nucleic acids into eukaryotic cells (e.g., stem cells) with high efficiency and low genotoxicity.